The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Articles by Marta Figueiredo, PhD
The gene therapy startup AavantiBio has launched with $107 million in funding to advance its lead clinical program…
The Centers of Medicare & Medicaid Services (CMS) has approved a new, specific diagnosis code for Friedreich’s ataxia…
Simultaneous suppression of two histone methyltransferases (HMTs) significantly increased the activity of the FXN gene in cells derived…
A safety and tolerability study of Larimar Therapeutics’ investigational therapy CTI-1601 has started dosing a third and final…
Children younger than age 8 with symptoms of Friedreich’s ataxia are at a higher risk of faster disease progression and earlier…
Altered regulation of a protein called actin may contribute to neurodegeneration in Friedreich’s ataxia, according to a study…
The COVID-19 pandemic has not affected the preclinical program of XCUR-FXN, an experimental treatment for Friedreich’s ataxia…
Design Therapeutics has launched with $45 million in funding to advance its lead candidate for the treatment of…
Physical impairments that worsen with disease progression are the main contributors to a poor health-related quality of life among people…